Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Domvanalimab

Administered intravenously

DRUG

Zimberelimab

Administered intravenously

DRUG

Paclitaxel

Administered intravenously

DRUG

Carboplatin

Administered intravenously

Trial Locations (25)

833

RECRUITING

Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

2145

RECRUITING

Westmead Hospital, Sydney

3004

RECRUITING

Alfred Health, Melbourne

3168

RECRUITING

Monash Health, Clayton

5037

RECRUITING

ICON Cancer Center, Kurralta Park

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

33308

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

33604

RECRUITING

CHU de Bordeaux, Pessac

37203

RECRUITING

Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research, Nashville

40402

RECRUITING

China Medical University Hospital, Taichung

41013

RECRUITING

Hospital Universitario Virgen del Rocio, Seville

63110

RECRUITING

Siteman Cancer Center, St Louis

77030

RECRUITING

The University of Texas, MD Anderson Cancer Center, Houston

80131

RECRUITING

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli

80756

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

93586

RECRUITING

Sarawak General Hospital, Sarawak

100229

RECRUITING

National Taiwan University Hospital, Taipei

200120

RECRUITING

Shanghai East Hospital, Shanghai

310005

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

430030

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

530012

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

610040

RECRUITING

Sichuan Cancer Hospital, Chengdu

EC1A 7BE

RECRUITING

Barts Health NHS Foundation Trust, London

SW10 9NH

RECRUITING

The Royal Marsden NHS Foundation Trust, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Arcus Biosciences, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT06727565 - Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma. | Biotech Hunter | Biotech Hunter